7+3

Multiple Myeloma: Update Bulletin #3 (2019) - Will the Approval of Split Dosing for Darzalex Result in Wider Uptake of the Drug? - ResearchAndMarkets.com

Retrieved on: 
Monday, July 15, 2019
Health, Other Health, Monoclonal antibodies, Clinical medicine, Drugs, Medicine, Breakthrough therapy, Daratumumab, Ice, Multiple myeloma, 7+3

The "Multiple Myeloma: Update Bulletin #3" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Multiple Myeloma: Update Bulletin #3" report has been added to ResearchAndMarkets.com's offering.
  • KOLs also give their views on the impact on clinical practice of the FDA's approval of a split-dose infusion regimen for the monoclonal antibody Darzalex (daratumumab; Johnson & Johnson).
  • Will the approval of split dosing for Darzalex result in wider uptake of the drug?
  • How warranted was the approval of a split-dosing regimen for Darzalex, given that Johnson & Johnson is currently developing a subcutaneous formulation of the drug?

Biotech Brief: Researchers Looking at New Bundled Treatment Options for Leukemia

Retrieved on: 
Wednesday, July 10, 2019
Cancer, Acute myeloid leukemia, RTT, Clinical medicine, Medicine, Leukemia, Chemotherapy, 7+3, Acute biphenotypic leukaemia, Acute eosinophilic leukemia

But the Society says that: "Researchers are now studying the causes, diagnosis, and treatment of acute myeloid leukemia (AML) at many medical centers, university hospitals, and other institutions.

Key Points: 
  • But the Society says that: "Researchers are now studying the causes, diagnosis, and treatment of acute myeloid leukemia (AML) at many medical centers, university hospitals, and other institutions.
  • As researchers have found more of these changes, it is becoming clear that there are many types of AML.
  • Each might have different gene changes that affect how the leukemia will progress and which treatments might be most helpful.
  • Chemotherapy is the main treatment for most types of AML but: " Researchers are now looking at ways to prevent or reverse this resistance by using other drugs along with chemo.

Biotech Brief: Researchers Looking at New Bundled Treatment Options for Leukemia

Retrieved on: 
Wednesday, July 10, 2019
Cancer, Acute myeloid leukemia, RTT, Clinical medicine, Medicine, Leukemia, Chemotherapy, 7+3, Acute biphenotypic leukaemia, Acute eosinophilic leukemia

But the Society says that: "Researchers are now studying the causes, diagnosis, and treatment of acute myeloid leukemia (AML) at many medical centers, university hospitals, and other institutions.

Key Points: 
  • But the Society says that: "Researchers are now studying the causes, diagnosis, and treatment of acute myeloid leukemia (AML) at many medical centers, university hospitals, and other institutions.
  • As researchers have found more of these changes, it is becoming clear that there are many types of AML.
  • Each might have different gene changes that affect how the leukemia will progress and which treatments might be most helpful.
  • Chemotherapy is the main treatment for most types of AML but: " Researchers are now looking at ways to prevent or reverse this resistance by using other drugs along with chemo.

Flexipharm Austrading Announces Launch of Arsenic Trioxide Phebra (Arsenic Trioxide 1mg/ml Concentrate for Solution for Infusion)

Retrieved on: 
Monday, May 20, 2019
Chemistry, Chemical elements, Physical sciences, Hepatotoxins, Oxides, Arsenic trioxide, Sesquioxides, Acute myeloid leukemia, Arsenic, Acute promyelocytic leukemia, Trioxide, 7+3

Critical Care Medicines, today announced the commercial availability in the UK of its differentiated arsenic trioxide injection product, Arsenic Trioxide Phebra, following the successful grant of a Marketing Authorisation by the MHRA.

Key Points: 
  • Critical Care Medicines, today announced the commercial availability in the UK of its differentiated arsenic trioxide injection product, Arsenic Trioxide Phebra, following the successful grant of a Marketing Authorisation by the MHRA.
  • Arsenic Trioxide Phebra is a glass vial presentation of arsenic trioxide 1mg/ml concentrate solution for infusion, a NICE-recommended treatment (in combination with all-trans retinoic acid) for newly diagnosed low-intermediate risk and relapsed acute promyelocytic leukaemia or APML1,2.
  • Arsenic Trioxide Phebra is the first generic arsenic trioxide injection product to be launched in the UK and the first in a preferred vial presentation.
  • Commenting on the launch, Michael Clark, Founder and Director of Flexipharm Austrading, said: "I am delighted and proud to make Arsenic Trioxide Phebra available to the NHS.

Flexipharm Austrading Announces Launch of Arsenic Trioxide Phebra (Arsenic Trioxide 1mg/ml Concentrate for Solution for Infusion)

Retrieved on: 
Monday, May 20, 2019
Chemistry, Chemical elements, Physical sciences, Hepatotoxins, Oxides, Arsenic trioxide, Sesquioxides, Acute myeloid leukemia, Arsenic, Acute promyelocytic leukemia, Trioxide, 7+3

Critical Care Medicines, today announced the commercial availability in the UK of its differentiated arsenic trioxide injection product, Arsenic Trioxide Phebra, following the successful grant of a Marketing Authorisation by the MHRA.

Key Points: 
  • Critical Care Medicines, today announced the commercial availability in the UK of its differentiated arsenic trioxide injection product, Arsenic Trioxide Phebra, following the successful grant of a Marketing Authorisation by the MHRA.
  • Arsenic Trioxide Phebra is a glass vial presentation of arsenic trioxide 1mg/ml concentrate solution for infusion, a NICE-recommended treatment (in combination with all-trans retinoic acid) for newly diagnosed low-intermediate risk and relapsed acute promyelocytic leukaemia or APML1,2.
  • Arsenic Trioxide Phebra is the first generic arsenic trioxide injection product to be launched in the UK and the first in a preferred vial presentation.
  • Commenting on the launch, Michael Clark, Founder and Director of Flexipharm Austrading, said: "I am delighted and proud to make Arsenic Trioxide Phebra available to the NHS.

Tolero Pharmaceuticals to Highlight Clinical Data Evaluating Investigational Agent Alvocidib in Patients with Newly Diagnosed AML at EHA 2019

Retrieved on: 
Thursday, May 16, 2019
Drugs, Chemical compounds, Organic compounds, Lactams, RTT, Orphan drugs, Protein kinase inhibitors, Chromones, Myelodysplastic syndrome, Decitabine, 7+3, Daunorubicin/cytarabine

Alvocidib is also being evaluated in Zella 101, a Phase I clinical study evaluating the maximum tolerated dose, safety and clinical activity of alvocidib in combination with cytarabine/daunorubicin(7+3) in newly diagnosed patients with AML ( NCT03298984 ), and Zella 102, a Phase 1b/2 study in patients with myelodysplastic syndromes (MDS) in combination with decitabine ( NCT03593915 ).

Key Points: 
  • Alvocidib is also being evaluated in Zella 101, a Phase I clinical study evaluating the maximum tolerated dose, safety and clinical activity of alvocidib in combination with cytarabine/daunorubicin(7+3) in newly diagnosed patients with AML ( NCT03298984 ), and Zella 102, a Phase 1b/2 study in patients with myelodysplastic syndromes (MDS) in combination with decitabine ( NCT03593915 ).
  • In addition, alvocidib is being evaluated in a Phase 1 study in patients with relapsed or refractory AML in combination with venetoclax ( NCT03441555 ).
  • Tolero Pharmaceuticals is based in the United States and is an indirect, wholly-owned subsidiary of Sumitomo Dainippon Pharma Co., Ltd., a pharmaceutical company based in Japan.
  • Any forward-looking statements set forth in this press release speak only as of the date of this press release.

AVEO Reports First Quarter 2019 Financial Results and Provides Business Update

Retrieved on: 
Thursday, May 9, 2019
Health, Biotechnology, Clinical trials, Oncology, Pharmaceutical, Other Health, Professional services, Banking, Finance, Cars, Clinical medicine, Cancer, Hatchbacks, Sedans, Subcompact cars, Oncology, Ficlatuzumab, Chevrolet Aveo, 7+3, Asco, Cytarabine

AVEO Oncology (NASDAQ: AVEO) today reported financial results for the first quarter ended March 31, 2019 and provided a business update.

Key Points: 
  • AVEO Oncology (NASDAQ: AVEO) today reported financial results for the first quarter ended March 31, 2019 and provided a business update.
  • Announced Positive Results from Phase 1b Ficlatuzumab-Cytarabine Trial (CyFi) in Patients with Relapsed and Refractory AML.
  • Presented Topline Results from TIVO-3 in an Oral Presentation at the 2019 ASCO Genitourinary Cancers Symposium and Announced Updated NDA Timing.
  • While AVEO may elect to update these forward-looking statements at some point in the future, it specifically disclaims any obligation to do so.

Global Chemotherapy Drugs Market is projected to display a robust growth represented by a CAGR of 11.91% during 2018 - 2023

Retrieved on: 
Tuesday, May 7, 2019
Cancer, Medicine, Clinical medicine, Antineoplastic drugs, Oncology, Chemotherapy, Occupational safety and health, Antibiotic, Antimetabolite, Alkaloid, 7+3

The report analyzes the Chemotherapy Drugs Market, By Type of Drug (Antimetabolites, Plant Alkaloids, Alkylating Agents, Antitumor Antibiotics, Others), By Route of Administration (Oral, Intravenous, Others).

Key Points: 
  • The report analyzes the Chemotherapy Drugs Market, By Type of Drug (Antimetabolites, Plant Alkaloids, Alkylating Agents, Antitumor Antibiotics, Others), By Route of Administration (Oral, Intravenous, Others).
  • Amongst the regions, North America accounts for the largest regional share in the global chemotherapy drugs market in 2018.
  • Besides, the report also identifies and analyses the emerging trends along with major drivers, challenges and opportunities in the global chemotherapy drugs market.
  • Reportlinker finds and organizes the latest industry data so you get all the market research you need - instantly, in one place.

GlycoMimetics Announces Enrollment of First Patient in NCI-Sponsored Phase 3 Trial of Uproleselan in AML

Retrieved on: 
Tuesday, April 23, 2019
Health, Biotechnology, Clinical trials, Oncology, Pharmaceutical, Research, Science, Cancer treatments, Chemical compounds, Cancer, Antibody-drug conjugates, Orphan drugs, Acute myeloid leukemia, RTT, 7+3, Lactams, Midostaurin, Vadastuximab talirine

A third trial, to be conducted by the European HOVON consortium, is expected to initiate later this year.

Key Points: 
  • A third trial, to be conducted by the European HOVON consortium, is expected to initiate later this year.
  • Along with our global pivotal Phase 3 clinical trial testing the investigational drug in patients with relapsed/refractory acute myeloid leukemia, this trial will facilitate our growing understanding of how uproleselan may fit into the continuum of care for individuals living with AML.
  • In a Phase 1/2 clinical trial, uproleselan was evaluated in both newly diagnosed elderly and relapsed/refractory patients with AML.
  • GlycoMimetics'wholly owned drug candidate, uproleselan, an E-selectin antagonist, was evaluated in a Phase 1/2 clinical trial as a potential treatment for AML and is being evaluated across a range of patient populations including a company-sponsored Phase 3 trial in relapsed/refractory AML.

Global Chemotherapy Drugs Markets 2019 by Drug Type, Administration & Region - Opportunities and Forecast 2013-2023

Retrieved on: 
Tuesday, April 16, 2019
Cancer, Clinical medicine, Medicine, Antineoplastic drugs, Chemotherapy, Occupational safety and health, Oncology, Antibiotic, Antimetabolite, 7+3

DUBLIN, April 16, 2019 /PRNewswire/ -- The "Global Chemotherapy Drugs Market: Analysis By Drug Type (Antimetabolites, Plant Alkaloids, Alkylating Agents, Antitumor Antibiotics), By Administration (Oral, Intravenous), By Region, By Country (2019 Edition): Opportunities and Forecast (2013-2023)" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • DUBLIN, April 16, 2019 /PRNewswire/ -- The "Global Chemotherapy Drugs Market: Analysis By Drug Type (Antimetabolites, Plant Alkaloids, Alkylating Agents, Antitumor Antibiotics), By Administration (Oral, Intravenous), By Region, By Country (2019 Edition): Opportunities and Forecast (2013-2023)" report has been added to ResearchAndMarkets.com's offering.
  • Amongst the regions, North America accounts for the largest regional share in the global chemotherapy drugs market in 2018.
  • The report has covered and analyzed the potential of global chemotherapy drugs market and provides statistics and information on market size, shares and growth factors.
  • Besides, the report also identifies and analyses the emerging trends along with major drivers, challenges and opportunities in the global chemotherapy drugs market.